89bio Inc.

About 89bio Inc.

89bio is a clinical-stage biopharmaceutical company dedicated to developing and delivering innovative therapies to treat patients with liver and cardiometabolic diseases, guided by medical need to provide treatments for those with limited or no approved options.

Products & Services

Pegozafermin (BIO89-100):An innovative therapy under development for liver and cardiometabolic diseases.

Specialties

Liver disease therapies Cardiometabolic disease therapies FGF21 metabolic regulation

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 287500000 MR: - FA: approximately $287.5 million FAN: 287500000	D: 2025-02-03 FD: 2025-02-03	4 investors
2	RT: Public Offering T: - FT: Public Offering	A: 250000000 MR: - FA: 250.0 million FAN: 250000000	D: 2025-01-28 FD: 2025-01-28	4 investors
3	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 250000000 MR: - FA: $250.0 million FAN: 250000000	D: 2025-01-27 FD: 2025-01-27	4 investors
4	RT: Public Offering T: - FT: Public Offering	A: 125000000 MR: - FA: $125.0 million FAN: 125000000	D: 2024-11-12 FD: 2024-11-12	3 investors
5	RT: Public Offering T: - FT: Public Offering	A: 100000000 MR: - FA: $100 million FAN: 100000000	D: 2024-11-12 FD: 2024-11-12	3 investors
6	RT: Public Offering T: - FT: Public Offering	A: 172500000 MR: - FA: 172.5 million FAN: 172500000	D: 2023-12-12 FD: 2023-12-12	6 investors
7	RT: Public Offering T: - FT: Public Offering	A: 150000000 MR: - FA: $150.0 million FAN: 150000000	D: 2023-12-07 FD: 2023-12-07	6 investors
8	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 125000000 MR: - FA: $125.0 million FAN: 125000000	D: 2023-12-06 FD: 2023-12-06	6 investors
9	RT: Public Offering T: - FT: Public Offering	A: 275000000 MR: - FA: $275 million FAN: 275000000	D: 2023-03-24 FD: 2023-03-24	5 investors
10	RT: Public Offering T: - FT: Public Offering	A: 200000000 MR: - FA: $200 million FAN: 200000000	D: 2023-03-22 FD: 2023-03-22	3 investors

Public Offering Latest

2025-02-03

$287.5M

4 investors (Pro only)

Public Offering 2025-01-28

$250.0M

Underwritten Public Offering 2025-01-27

$250.0M

View 9 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Rohan Palekar

Chief Executive Officer

H

Hank Mansbach

Chief Medical Officer

Q

Quoc Le-Nguyen

Chief Technical Officer

R

Ryan Martins

Chief Financial Officer

T

Teresa Perney

Chief Regulatory and Quality Officer

F

Francis Sarena

Chief Operating Officer

View 21 more team members with Pro

Unlock Full Team Directory

Recent News

89bio Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised